Short Term Rating on Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) has an average broker rating of 1.6, which is interpreted as a Buy, as rated by 5 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 considers that the stock is a Sell.

Halozyme Therapeutics (HALO) : 3 investment research analysts covering Halozyme Therapeutics (HALO) have an average price target of $12.58 for the near short term. The highest target price given by the Brokerage Firm to the stock is $16 and the lowest target is $7 for the short term. Analysts expect the variance to be within $5.08 of the average price.

For the current week, the company shares have a recommendation consensus of Buy.


Halozyme Therapeutics (NASDAQ:HALO): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.22 and $9.02 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.33. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.11, notching a gain of 0.33% for the day. The total traded volume was 1,373,339 . The stock had closed at $9.08 on the previous day.

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.